Tony McHale (pictured above) discovered he had an alteration in the BRCA2 gene at the age of 61, putting him at a much higher risk of developing prostate cancer. Shortly after, Tony joined the IMPACT ...

Drug resistance is a major clinical challenge in cancer treatment, underlying both tumour recurrence and patient mortality (Vasan et al, 2019). Yet when cancer cells develop resistance to a drug, ...

Cancer research studies check whether new treatments are safe and work as intended. People who take part in these studies should be similar to those affected by the cancer, from different ethnicities ...

Metastatic cells are characterised as being highly invasive but weakly adhesive with rounded-amoeboid like features. These cells harbour high levels of cortical Myosin II activity and exert low ...

1 in 5 people with prostate cancer are diagnosed after their cancer has spread beyond the prostate, making the chance of cure low. Despite improvements in the treatment of advanced prostate cancer, ...

In a major step forward for cancer drug discovery, researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug ...

DJ and music promoter, Godfrey Fletcher, was diagnosed with prostate cancer in 2015 at the age of 47, shortly after his father was also diagnosed with the same disease. Since then, Godfrey has made it ...

Advocacy engagement: policy and public affairs Our policy priorities Creating a sustainable funding model for research in universities Encouraging international talent to support cancer research ...

Our clinical PhD fellowships are provided to develop and support future leaders in clinical cancer research. The Clinical Academic Training Programme, ICR-Imperial is a programme which will provide ...

New research has ruled out hormone signalling as the reason why men with acute myeloid leukaemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy – ...